Data from Novartis' SPARK - Analyst Blog
April 23 2013 - 12:45PM
Zacks
Novartis AG (NVS)
recently announced positive results from its phase III study,
SPARK, spanning over 64 weeks.
The results showed that its
candidate QVA149 was more effective at reducing all chronic
obstructive pulmonary disease (COPD) exacerbations compared to
Seebri Breezhaler (glycopyrronium bromide 50 mcg) and open-label
Boehringer-Ingelheim/Pfizer’s (PFE) Spiriva
(tiotropium) 18 mcg.
We note that Novartis’ candidate
QVA149 is being studied for the treatment of chronic obstructive
pulmonary disease (COPD). The results were published in Lancet
Respiratory Medicine. The study met its primary endpoint of
significantly reducing the rate of moderate or severe COPD
exacerbations.
It was also observed that usage of
QVA149 can lead to significant improvements in lung function. SPARK
is one of the ten studies, which is evaluating QVA49 for the
treatment of COPD in the IGNITE phase III clinical trial program
spanning across 42 countries and involving 7,000 patients.
We note that other than QVA149,
Novartis’ COPD portfolio includes Onbrez Breezhaler (indacaterol
maleate), which was launched in the US under the brand name Arcapta
Neohaler and in Japan under the name Onbrez inhalation capsules
where it is being co-promoted by Eisai and Co. Ltd
(ESALY).
Onbrez Breezhaler reported a 39%
year over year growth in 2012 driven by strong demand. As per
Novartis, COPD affects approximately 210 million people across the
globe and is expected to become the third most important cause of
death by 2020. Thus, it provides ample commercial opportunities for
the candidate upon approval.
Novartis currently carries a Zacks
Rank #3. Right now, UCB SA (UCBJF) looks more
attractive with a Zacks Rank #1 (Strong Buy).
EISAI CO LTD (ESALY): Get Free Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jul 2023 to Jul 2024